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Introduction: Our objective was to examine the role of the janus-activated kinase (JAK) pathway in the modulation
of tumor necrosis factor-α (TNF)-induced-IL-18 bioactivity by reduction of caspase-1 function.
Methods: Caspase-1 expression in rheumatoid arthritis (RA) synovial fibroblasts treated with TNF was assessed by
qRT-PCR and Western blot. Interleukin (IL)-18 was assessed by enzyme-linked immunosorbent assay (ELISA) in cell
lysates and conditioned media and detected by immunofluorescence (IF) staining in RA synovial fibroblasts. The
critical pathways for TNF-induced caspase-1 expression were determined by using chemical inhibitors of signaling
followed by TNF stimulation. IL-18 bioactivity was assessed using human myelomonocytic KG-1 cells.
Results: TNF induced RA synovial fibroblast caspase-1 expression at the protein level in a time-dependant manner
(P < 0.05). Blocking the JAK pathway reduced TNF-induced-caspase-1 expression at the transcriptional and protein levels
by approximately 60% and 40%, respectively (P < 0.05). Blocking the JAK pathway reduced TNF-induced-caspase-1
expression at the transcriptional, protein, and activity levels by approximately 60%, 40%, and 53%, respectively
(P < 0.05). We then confirmed by IF that TNF-induced IL-18 and investigated roles of the ERK1/2 and JAK pathways.
Blocking the JAK pathway, TNF induced intracytoplasmic granular IL-18 expression suggesting a defect of caspase-1.
Finally, blocking the JAK pathway, we observed a reduction of IL-18 bioactivity by 52% in RA synovial fibroblasts
(P < 0.05).
Conclusions: These results provide a new way to regulate TNF-induced-IL-18 bioactivity by blocking capase-1. These
data present a novel role for JAK inhibition in RA patients and emphasize JAK inhibition use as a new therapeutic
option in RA management.Introduction
Rheumatoid arthritis (RA) is characterized by inflamed
synovial tissue containing a massive infiltration of lym-
phocytes and macrophages with synovial fibroblast prolif-
eration. IL-18, an IL-1 family member, is involved in RA
pathogenesis [1]. We and others have shown that IL-18
plays an important role in the immune response, in local
or systemic angiogenesis [2,3], and in monocyte recruit-
ment [4]. Various sources of IL-18 have been identified in-
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reproduction in any medium, provided the orarticular chondrocytes, osteoblasts, and synovial fibro-
blasts [5,6].
IL-18, is produced as a biologically inactive precursor
protein (pro-IL-18) containing a propeptide domain
localized to the cytoplasm. To be activated, pro-IL-18
requires cleavage by the IL-1β-converting enzyme
(ICE), which is a member of the aspartate-specific
cysteine protease family (caspase-1). Caspase-1 is pro-
duced as an inactive form. To be activated, its needs to
be cleaved into 20 kDa and 10 kDa subunits. Both sub-
units form heterodimers with interactions with other
proteins and are involved in inflammasome formation
and activation of inflammatory processes [7]. Active
caspase-1 is located in the plasma membrane, where it
cleaves pro-IL-18 (inactive) to IL-18 (still inactive).
Caspase-1 and pro-IL-18/IL-18 are complexed to otherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Caspase-1 is also a critical putative target in patients with
cryopyrin-associated periodic syndromes (CAPS) [10].
When IL-18 is secreted, it becomes active [11]. IL-18
bioactivity is dependent on both IL-18 and IL-18 binding
protein (IL-18BP, its natural inhibitor) levels [5,6].
Among various signaling pathways, the mitogen-
activated protein kinase (MAPK) family, nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
and janus-activated kinase (JAK) pathways are thought
to be critical in RA pathogenesis [12]. All these pathways
can be activated by TNF-α [5,6]. We previously des-
cribed ways to regulate TNF-induced IL-18 bioactivity
in RA synovial fibroblasts by modulation of IL-18
or IL-1BP [5,6]. Here, we explore regulation of TNF-
induced IL-18 bioactivity by reduction of TNF-induced
caspase-1 in RA synovial fibroblasts.
Methods
Cytokines, culture of human RA synovial fibroblasts, and
chemical inhibitors
TNF was purchased from R&D Systems (Minneapolis,
MN, USA). Fibroblasts were isolated from RA synovium
obtained from RA patients undergoing arthroplasty or
synovectomy as described previously [5,6]. For all hu-
man specimens used in this study, we obtained written
informed consent and all aspects of the study were
approved by the University of Michigan Institutional
Review Board. Allergies were not reported and no skin
tests were performed on these RA patients. MAPK
inhibitors (ERK1/2, PD98059; p38, SB202190; and JNK2,
SP600125), an NF-κB inhibitor (pyrrolidine dithiocarba-
mate (PDTC)), or a JAK2 inhibitor (AG490) were used
at 10 μM of each inhibitor, except PDTC at 200 μM
[5,6]. All inhibitors were purchased from Calbiochem
(San Diego, CA, USA). All experiments were performed
in serum-free media except experiments for IL-18
detection.
Cell lysis and western blotting
To study the effect of TNF on caspase-1 expression, RA
synovial fibroblasts were incubated with TNF (20 ng/ml)
in RPMI 1640 and processed, as previously described
[5,6]. We used a rabbit anti-human caspase-1 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) over-
night at 4°C and then horseradish peroxidase-conjugated
antibody (1:1,000 dilution) for 1 hour at room tem-
perature. Blots were scanned and analyzed for band
intensities, as previously described [5,6].
Caspase-1 activity assay
RA synovial fibroblasts (2 × 106/well) were pre-incubated
with the chemical inhibitors (described above) for 2 hours
and then treated with TNF (20 ng/ml) for 24 hours inserum-free RPMI 1640. Cells were washed and then lysed
with the lysis buffer from the caspase-1 activity assay kit.
Cell lysates were centrifuged, and the supernatant was
assessed. Caspase-1 activity in the supernatant was deter-
mined using a colorimetric caspase-1 activity assay kit
(R&D Systems).
IL-18 detection in conditioned media
RA synovial fibroblasts were stimulated with TNF
(20 ng/ml) in RPMI 1640 with 10% fetal bovine serum
(FBS) supplementation for 72 hours. Conditioned me-
dium was collected and concentrated 10-fold using
Amicon Ultra 3,000 MW concentrators from Millipore
(Bedford, MA, USA). Equal volumes of conditioned
media were loaded and processed for western blotting as
previously described above except that primary poly-
clonal rabbit anti-human IL-18 antibody was used (Santa
Cruz biotechnology, Santa Cruz, CA, USA).
ELISA for IL-18 and IL-18BP
RA synovial fibroblasts were stimulated with TNF for 8
to 48 hours in RPMI with 10% FBS and conditioned
medium was collected and concentrated as described
above. IL-18 was assessed in conditioned media and cell
lysates using an ELISA kit from Bender MedSystems
(Burlingame, CA, USA). IL-18BP was assessed in condi-
tioned media using an ELISA kit from R&D Systems.
RNA extraction and quantitative real time-polymerase
chain reaction (qRT-PCR)
Following the manufacturer’s protocol, RNA was isolated
from RA synovial fibroblasts and processed as described
previously [5,6]. We used specific primer sequences for
caspase-1: forward: 5′-AGCCAACATGCCCATCACTC
GG-3′, reverse: 5′- TGCTACGGTGCACAGGGAAT
GG -3′; and for β-actin: forward: 5′-GTCAGGCAGCT
CGTAGCTCT-3′, reverse: 5′-GCCATGTACGTTGC
TATCCA-3′ and the following cycles: 50°C for 2 minutes,
95°C for 2 minutes, and 40 cycles of 95°C for 30 seconds,
55°C for 30 seconds, and 68°C for 30 seconds. For quantifi-
cation, the relative abundance of each gene was normalized
to β-actin.
IL-18 bioactivity
The biologic activity of IL-18 was measured using human
myelomonocytic KG-1 cells, as previously described [5,6].
KG-1 cells (3 × 106 cells/ml; 100 μL), with or without
mouse monoclonal anti-IL-18 antibody at 1 μg/ml (R&D
Systems), were dispensed into the wells of 96-well Falcon
microtiter plates (Becton Dickinson). Next, 100 μL of
samples or recombinant human IL-18 standard was added
to each well. The plates were incubated, and culture
supernatants were harvested 24 hours later. The IFNγ
concentration in this media was determined by ELISA
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determined based on the difference in IFNγ levels bet-
ween cultures with and those without mouse anti-IL-18
monoclonal antibody.
Immunofluorescence staining
RA synovial fibroblasts were plated in 8-well Labtek
chamber slides and processed as described previously
[6]. Briefly, cells were untreated or stimulated with TNF
(20 ng/ml) for 48 hours with or without preincubation
with PD98059 or AG490 for 2 hours. After 48 hours,
cells were washed, fixed, permeabilized, and blocked.
IL-18 primary antibody (10 μg/ml), which reacts with
both immature and mature IL-18 forms, was used after
washing in combination with Alexa Fluor-conjugated goat
anti-rabbit antibody. After washing, nuclei were stained
with 4′,6′-diamidino-2-phenylindole (Invitrogen). Slides
were dehydrated, mounted, and coverslipped. Immuno-
fluorescence (IF) staining was detected using an Olympus
FV-500 microscope (Olympus America, Melville, NY,
USA).5 
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Figure 1 TNF-induced functional caspase-1 in rheumatoid arthritis (RA
2 ml/well) were stimulated with TNF in serum-free media for 0 to 48 hours. C
shown are specific for active caspase-1. Bars show the mean and standard err
different donors (A). RA synovial fibroblasts (2 × 105/well in 6-well plates; 2 ml
detected by western blotting in 10-times concentrated conditioned media. A
donors is shown (B). RA synovial fibroblasts (2 × 105/well in 6-well plates; 2 m
with 10% FBS. IL-18 protein induction was assessed by ELISA in concentrated
mean of fold induction with SEM. *P <0.05 versus non stimulated (NS).Statistical analysis
Statistically significant differences between groups were
calculated using Student’s t-test. P-values less than
0.05 were considered significant. All statistical data are
expressed as the mean ± standard error of the mean
(SEM).
Results
TNF induced functional caspase-1 in RA synovial
fibroblasts
To determine whether pro-IL-18 was potentially cleaved
by active caspase-1 to the IL-18 active form, we exa-
mined caspase-1 expression in cell lysates and IL-18
expression in cell lysates and conditioned media at the
protein level, without or with TNF stimulation. TNF
induced caspase-1 at the protein level in cell lysates in
a time-dependent manner (Figure 1A) and the mature
IL-18 secretion in the conditioned media assessed by
western blot and ELISA (Figure 1B,C). The pro-IL-18
level in cell lysates did not change over time (Figure 1D),
suggesting that pro-IL-18 is cleaved to IL-18 and then 0.05 
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caspase-1 to cleave pro-IL-18.
Role of the JAK pathway in TNF-induced caspase-1
To identify signaling events that are critical for TNF-
induced caspase-1, RA synovial fibroblasts were in-
cubated with chemical signaling inhibitors for 2 hours,
followed by TNF stimulation. Only JAK pathway40 
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JAK pathway strongly reduced TNF-induced caspase-
1 activity (P <0.05; n = 3; Figure 2C). Furthermore,
blocking the JNK pathway already slightly decreased
the TNF-induced caspase-1 activity (P <0.05; n = 3;
Figure 2C). These data indicate that the JAK pathway
is a critical pathway for TNF-induced caspase-1 and
IL-18 bioactivity.NSControl
TNF + PD98059
Caspase-1 
TNF
R
ec
ep
to
r 
R
ec
ep
to
r 
I
IL-18 bioactivity
+ - 
pro-IL-18 
Jak 
IL-18 
A 
F 
B 
D 
IL-18 
Figure 3 Localization of IL-18 on rheumatoid arthritis (RA) synovial fi
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detected in the cytoplasm with some granularity (E). Images shown are repre
TNF induction of mature IL-18 by induction of functional caspase-1 through tBlocking JAK results in reduction of TNF-induced IL-18
bioactivity in RA synovial fibroblasts
After showing the key role of JAK in TNF-induced
caspase-1 expression and activity, we assessed its function
on maturation of IL-18. In conditioned media, JAK block-
ade potently decreased TNF-induced IL-18 (P < 0.05;
n = 4; Figure 2D), whereas IL-18BP was not affected
(Figure 2F). In cell lysates, when JAK was blocked,TNF
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secretion (P <0.05; n = 4; Figure 2E). As IL-18 bioactivity
is the result of the balance between mature secreted IL-18
and IL-18BP, we explored IL-18 bioactivity in the same
conditioned media using KG-1 cells. We confirmed that
TNF induced IL-18 bioactivity and this induction was re-
duced by 52% after blockade of the JAK pathway
(P <0.05; n = 4; Figure 2G). The data confirmed that blocking
the JAK pathway reduced IL-18 bioactivity without effect
on IL-18BP.
Blocking caspase-1 results in inhibition of release of IL-18
IL-18 expression inside the cell was detected using IF in
various stimulation conditions. We confirmed induction
of expression of pro-IL-18 by TNF (Figure 3C). To vali-
date this assay, we blocked the ERK pathway, which was
previously reported to be critical for TNF-induced-pro-
IL-18 and observed inhibition of IL-18 after TNF stimula-
tion (Figure 3D) [5]. Additionally upon blocking JAK, we
observed an intracytoplasmic granular staining (Figure 3E).
This suggests accumulation of pro-IL-18 without secre-
tion, suggesting a lack of effect of caspase-1. These results
indicate a crucial role of the JAK pathway in regulating
TNF-induced IL-18 bioactivity (Figure 3F). The data
confirmed that blocking the JAK pathway reduced
IL-18 bioactivity by IL-18 maturation reduction.
Discussion
Compared to other pro-inflammatory cytokines, IL-18 is
highly regulated at the expression, maturation, and bio-
activity levels. Constitutive IL-18 mRNA and protein in
the precursor form are present in non stimulated human
cells and in untreated tissues [13]. Without stimulation,
IL-18 is primarily present in the precursor form, which
requires conversion by caspase-1 to the mature and bio-
active form [11]. The membrane-bound form of IL-18
was recently described to be caspase-1 dependent and
restricted to a subgroup of monocytes [14].
Here, we confirmed that TNF induced caspase-1 in a
time-dependent manner at both protein and activity
levels in RA synovial fibroblasts, as previously suggested
[5]. We also confirmed that TNF induced IL-18 ex-
pression and secretion from RA synovial fibroblasts [5].
IL-18 in the conditioned media after TNF induction sug-
gested the presence of functional TNF-induced caspase-1.
This is consistent with previous data showing that TNF
induces IL-1β [15].
AG490 is mainly a strong inhibitor of JAK2. However,
it was described to also inhibit the JAK3 pathway.
Hence, these inhibitors are not specific enough to claim
JAK2 specificity. We previously described that the JAK
pathway was not involved in TNF-induced IL-18 or
IL-18BP in the same in vitro model [5]. As a result, in
this model of IL-18 bioactivity induced by TNF, wedescribe a new way to reduce IL-18 bioactivity by regula-
tion of caspase-1. Previously, we observed that the ERK
pathway was critical for IL-18 expression [5], whereas
the JNK-2 and NF-κB pathways were important for
IL-18BP expression [6]. Compared to our previous
results, we found a new specific pathway for regulating
IL-18 bioactivity, that is, the JAK pathway.
TNF induces many intracellular signaling pathways. The
JAK pathway is activated by TNF through its binding to
its type I receptor [16]. Furthermore, expression of che-
mokines induced by TNF was reduced by blocking the
JAK pathway in RA synovial fibroblasts [17] and in RA
synovial macrophages [18]. So in this model, blocking the
JAK2 pathway specifically reduced TNF-induced IL-18
bioactivity only by reduction of IL-18 secretion due to
inhibition of functional caspase-1. In vivo, JAK2 pathway
inhibition has been shown to improve inflammatory arth-
ritis in a rodent model [19] and blocking JAK1/3 has been
shown to reduce joint destruction [20]. JAK inhibitors
suppress both innate and adaptative immunity in the
K/BxN serum transfer model [18]. In human RA, JAK
inhibitors are a new attractive therapeutic option for RA
management [21].
Conclusions
These results provide a novel way to regulate TNF-
induced-IL-18 bioactivity by blocking capase-1. These
results suggest an additional mechanism to explain the
beneficial effect of JAK inhibitors in RA.
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